Targeting WNT/β-Catenin via Modulating EZH2 Function: A New Chapter in the Treatment of β-Catenin Mutant Hepatocellular Carcinoma?
- PMID: 37747420
- DOI: 10.1158/0008-5472.CAN-23-2921
Targeting WNT/β-Catenin via Modulating EZH2 Function: A New Chapter in the Treatment of β-Catenin Mutant Hepatocellular Carcinoma?
Abstract
In a recent study, Rialdi and colleagues identified a specific vulnerability in β-catenin mutant hepatocellular carcinoma (HCC) via EZH2-mediated suppression of WNT signaling and revealed the selective anti-HCC activity of WNTinib, a chemical derivative of regorafenib and sorafenib in targeting this vulnerability. Their discoveries highlight the role of EZH2 in modulating WNT signaling and suggest an implication of WNTinihb as a small-molecule inhibitor for the treatment of HCC with activated WNT/β-catenin.
©2023 American Association for Cancer Research.
Comment on
-
WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma.Nat Cancer. 2023 Aug;4(8):1157-1175. doi: 10.1038/s43018-023-00609-9. Epub 2023 Aug 3. Nat Cancer. 2023. PMID: 37537299 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical